Filing Flows

Filing Flows › Mesa Laboratories (MLAB) › Q3 FY25

Mesa Laboratories (MLAB) Q3 FY25 earnings results (third quarter fiscal 2025)

10-Q filed Feb 4, 2025

Mesa Laboratories (MLAB) reported revenue of $62.8M for the third quarter fiscal 2025 (Q3 FY25), +18% from a year earlier and +9% from the quarter before. Operating margin was 9.2%, net loss $1.7M (2.7% of revenue).

Revenue$62.8M
Year over year+18%
Quarter over quarter+9%
Operating margin9.2%
Net earnings−$1.7M

Mesa Laboratories, Q3 FY25: revenue $62.8M (+18% year over year), operating margin 9.2%, net loss $1.7M, operating cash flow $18.1M. The chart follows the revenue to costs, profit and cash.

Q3 FY25AmountQ/QY/Y
Revenue$62.8M+9%+18%
Operating profit$5.8M——
Net earnings−$1.7M——
Operating cash flow$18.1M+244%+57%
Free cash flow$17.3M+397%+66%

What changed

Revenue was $62.8M in Q3 FY25, up 18% year over year and up 9% from the previous quarter.

Gross margin was 63.3%, up 0.8 points from a year earlier. Operating profit was $5.8M, a 9.2% margin (up 9.3 points year over year). Operating expenses grew 2% against revenue growth of 18%. The fastest-growing cost line was Research & development (+18%). The quarter ended with a net loss of $1.7M, after a profit of $3.4M the previous quarter. Net interest and other expense of $8.0M was the main reason.

Operating cash flow was $18.1M (up 57% year over year). Non-cash charges added back $5.5M of depreciation and amortization and $3.2M of share-based compensation. Working capital and other items added $11.1M. Capital expenditures of $813K left free cash flow of $17.3M.

Questions

What was Mesa Laboratories' revenue in the third quarter fiscal 2025?

Mesa Laboratories (MLAB) reported revenue of $62.8M for the third quarter fiscal 2025 (Q3 FY25), +18% from a year earlier and +9% from the quarter before.

Was Mesa Laboratories profitable in the third quarter fiscal 2025?

Operating profit was $5.8M (9.2% of revenue) and net loss $1.7M.

Open the interactive Sankey →

Source: Mesa Laboratories 10-Q on SEC EDGAR.